FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385606449> ?p ?o ?g. }

• W4385606449 endingPage "3979" @default.
• W4385606449 startingPage "3979" @default.
• W4385606449 abstract "Stereotactic body radiation therapy (SBRT) has made the hypofractionation of high doses delivered in a few sessions more acceptable. While the benefits of hypofractionated SBRT have been attributed to additional vascular, immune effects, or specific cell deaths, a radiobiological and mechanistic model is still needed. By considering each session of SBRT, the dose is divided into hundreds of minibeams delivering some fractions of Gy. In such a dose range, the hypersensitivity to low dose (HRS) phenomenon can occur. HRS produces a biological effect equivalent to that produced by a dose 5-to-10 times higher. To examine whether HRS could contribute to enhancing radiation effects under SBRT conditions, we exposed tumor cells of different HRS statuses to SBRT. Four human HRS-positive and two HRS-negative tumor cell lines were exposed to different dose delivery modes: a single dose of 0.2 Gy, 2 Gy, 10 × 0.2 Gy, and a single dose of 2 Gy using a non-coplanar isocentric minibeams irradiation mode were delivered. Anti-γH2AX immunofluorescence, assessing DNA double-strand breaks (DSB), was applied. In the HRS-positive cells, the DSB produced by 10 × 0.2 Gy and 2 Gy, delivered by tens of minibeams, appeared to be more severe, and they provided more highly damaged cells than in the HRS-negative cells, suggesting that more severe DSB are induced in the “SBRT modes” conditions when HRS occurs in tumor. Each SBRT session can be viewed as hyperfractionated dose delivery by means of hundreds of low dose minibeams. Under current SBRT conditions (i.e., low dose per minibeam and not using ultra-high dose-rate), the response of HRS-positive tumors to SBRT may be enhanced significantly. Interestingly, similar conclusions were reached with HRS-positive and HRS-negative untransformed fibroblast cell lines, suggesting that the HRS phenomenon may also impact the risk of post-RT tissue overreactions." @default.
• W4385606449 created "2023-08-06" @default.
• W4385606449 creator A5003366087 @default.
• W4385606449 creator A5010392559 @default.
• W4385606449 creator A5025970052 @default.
• W4385606449 creator A5026718322 @default.
• W4385606449 creator A5028157415 @default.
• W4385606449 creator A5048654044 @default.
• W4385606449 creator A5058092517 @default.
• W4385606449 creator A5060355540 @default.
• W4385606449 creator A5066266071 @default.
• W4385606449 creator A5066321166 @default.
• W4385606449 creator A5067730699 @default.
• W4385606449 creator A5072623725 @default.
• W4385606449 creator A5081937285 @default.
• W4385606449 creator A5084692010 @default.
• W4385606449 date "2023-08-05" @default.
• W4385606449 modified "2023-09-27" @default.
• W4385606449 title "Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy" @default.
• W4385606449 cites W1572112831 @default.
• W4385606449 cites W1975424226 @default.
• W4385606449 cites W1975664090 @default.
• W4385606449 cites W1978509389 @default.
• W4385606449 cites W1999420331 @default.
• W4385606449 cites W2012924416 @default.
• W4385606449 cites W2014771865 @default.
• W4385606449 cites W2019219567 @default.
• W4385606449 cites W2027465496 @default.
• W4385606449 cites W2030528631 @default.
• W4385606449 cites W2033474360 @default.
• W4385606449 cites W2034825514 @default.
• W4385606449 cites W2039611104 @default.
• W4385606449 cites W2095418105 @default.
• W4385606449 cites W2096200284 @default.
• W4385606449 cites W2102735542 @default.
• W4385606449 cites W2107943906 @default.
• W4385606449 cites W2122738468 @default.
• W4385606449 cites W2126220821 @default.
• W4385606449 cites W2140186362 @default.
• W4385606449 cites W2141558124 @default.
• W4385606449 cites W2161456141 @default.
• W4385606449 cites W2165631314 @default.
• W4385606449 cites W2171329552 @default.
• W4385606449 cites W2224472562 @default.
• W4385606449 cites W2297597472 @default.
• W4385606449 cites W2321231819 @default.
• W4385606449 cites W2340890692 @default.
• W4385606449 cites W2514551091 @default.
• W4385606449 cites W2767455845 @default.
• W4385606449 cites W2882971600 @default.
• W4385606449 cites W2887878798 @default.
• W4385606449 cites W2909212000 @default.
• W4385606449 cites W2954099051 @default.
• W4385606449 cites W2967518430 @default.
• W4385606449 cites W2969879421 @default.
• W4385606449 cites W2983991514 @default.
• W4385606449 cites W2990934897 @default.
• W4385606449 cites W3005082545 @default.
• W4385606449 cites W3016428926 @default.
• W4385606449 cites W3120281345 @default.
• W4385606449 cites W3162444084 @default.
• W4385606449 cites W4210652399 @default.
• W4385606449 cites W4220831017 @default.
• W4385606449 cites W4292291686 @default.
• W4385606449 cites W4295213563 @default.
• W4385606449 doi "https://doi.org/10.3390/cancers15153979" @default.
• W4385606449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37568795" @default.
• W4385606449 hasPublicationYear "2023" @default.
• W4385606449 type Work @default.
• W4385606449 citedByCount "0" @default.
• W4385606449 crossrefType "journal-article" @default.
• W4385606449 hasAuthorship W4385606449A5003366087 @default.
• W4385606449 hasAuthorship W4385606449A5010392559 @default.
• W4385606449 hasAuthorship W4385606449A5025970052 @default.
• W4385606449 hasAuthorship W4385606449A5026718322 @default.
• W4385606449 hasAuthorship W4385606449A5028157415 @default.
• W4385606449 hasAuthorship W4385606449A5048654044 @default.
• W4385606449 hasAuthorship W4385606449A5058092517 @default.
• W4385606449 hasAuthorship W4385606449A5060355540 @default.
• W4385606449 hasAuthorship W4385606449A5066266071 @default.
• W4385606449 hasAuthorship W4385606449A5066321166 @default.
• W4385606449 hasAuthorship W4385606449A5067730699 @default.
• W4385606449 hasAuthorship W4385606449A5072623725 @default.
• W4385606449 hasAuthorship W4385606449A5081937285 @default.
• W4385606449 hasAuthorship W4385606449A5084692010 @default.
• W4385606449 hasBestOaLocation W43856064491 @default.
• W4385606449 hasConcept C111337013 @default.
• W4385606449 hasConcept C121332964 @default.
• W4385606449 hasConcept C126838900 @default.
• W4385606449 hasConcept C18231593 @default.
• W4385606449 hasConcept C185544564 @default.
• W4385606449 hasConcept C2780387249 @default.
• W4385606449 hasConcept C2989005 @default.
• W4385606449 hasConcept C509974204 @default.
• W4385606449 hasConcept C71924100 @default.
• W4385606449 hasConceptScore W4385606449C111337013 @default.
• W4385606449 hasConceptScore W4385606449C121332964 @default.
• W4385606449 hasConceptScore W4385606449C126838900 @default.

• next